SCHEMBL13323

SCHEMBL13323

O=C1CSc2ccccc2N1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
MAOA P21397 7/20 0.59
MAOB P27338 6/20 0.59
EPHX2 P34913 1/20 0.59
HTT P42858 1/20 0.53
BRD4 O60885 1/20 0.51
CREBBP Q92793 1/20 0.51
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 1/20 0.47
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
BCHE P06276 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46
ADORA3 P0DMS8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30648399 0.98 ALDH1A1 (0.58) ALDH1A1MAOAMAOBEPHX2HTT
SCHEMBL3831209 0.83 MAOA (0.44) ALDH1A1MAOAMAOBEPHX2HTT
SCHEMBL6345921 0.80 ALDH1A1 (0.56) ALDH1A1MAOAMAOBEPHX2HTT
SCHEMBL1756087 0.80 HDAC1 (0.51) ALDH1A1MAOAEPHX2BRD4CREBBP
SCHEMBL9628996 0.77 MAPT (0.53) ALDH1A1MAOAMAOBEPHX2BRD4
SCHEMBL7998823 0.77 MAOB (0.53) ALDH1A1MAOAMAOBEPHX2HTT
SCHEMBL4653865 0.77 HTT (0.62) ALDH1A1MAOAMAOBEPHX2HTT
SCHEMBL4258367 0.77 HTT (0.59) ALDH1A1MAOAMAOBEPHX2HTT
Phenothiazine SCHEMBL29051430 0.77 GSK3A (0.58) ALDH1A1MAOAMAOBEPHX2HTT
SCHEMBL3428710 0.76 L3MBTL1 (0.50) ALDH1A1MAOAMAOBEPHX2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 724 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720318-A1 METHODS AND COMPOSITIONS FOR THE PRODUCTION OF GLYOXAL Solugen, Inc. (US) 2026-04-08 EP claimed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP claimed
US-12390473-B2 Methods of treating tyrosine kinase inhibitor-induced diarrhea THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-08-19 US claimed
EP-4583977-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-07-16 EP claimed
US-20250178995-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF GLUCARIC ACID SOLUGEN, INC. (US) 2025-06-05 US claimed
WO-2025076549-A1 SMALL MOLECULE ACTIVATORS SOLUGEN, INC. (US) 2025-04-10 WO claimed
WO-2024249896-A1 METHODS AND COMPOSITIONS FOR THE PRODUCTION OF GLYOXAL SOLUGEN, INC. (US) 2024-12-05 WO claimed
WO-2024170772-A1 EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA MIM NEUROSCIENCES AB (SE) 2024-08-22 WO claimed
WO-2024052512-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-14 WO claimed
CN-111886233-B Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same 柳韩洋行 2024-01-02 CN claimed
EP-1362577-B1 Hair dye composition KAO CORP (JP) 2006-07-12 EP claimed
EP-1362577-A1 Hair dye composition Kao Corporation (JP) 2003-11-19 EP claimed
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors BERRYMAN KENT ALAN (US) 2003-10-02 US claimed
EP-1068191-A1 BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2001-01-17 EP claimed
EP-0627425-B1 3-OXO-1,4-BENZOTHIAZINE DERIVATIVE SANTEN PHARMACEUTICAL CO LTD (JP) 2000-11-02 EP claimed
WO-1999050257-A1 BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-10-07 WO claimed
EP-0463945-B1 Chalcone derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1995-12-27 EP claimed
EP-0463945-A1 Chalcone derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1992-01-02 EP claimed
US-4535079-A HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS; VASODILATORS MEDIOLANUM FARMACEUTICI S.R.L. (IT) 1985-08-13 US claimed
EP-0106816-A2 Alkanolaminoxy derivatives of 3,4-dihydro-2H-1,4-benzothiazin-3-one, their production process, and their pharmaceutical use MEDIOLANUM FARMACEUTICI s.r.l. (IT) 1984-04-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250178995-A1 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF GLUCARIC ACID G6PD, SOD1, UGDH ALDH1A1 229/4885MAOA 554/4885MAOB 1098/4885
US-12390473-B2 Methods of treating tyrosine kinase inhibitor-induced diarrhea CFTR, LCK, ABL1 ALDH1A1 3634/4885MAOA 4517/4885MAOB 3709/4885
US-20030187256-A1 Benoxazinones/benzothiazinones as serine protease inhibitors HABP2, SPINT2, SERPINB1 ALDH1A1 2444/4885MAOA 340/4885MAOB 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.